Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
The main objective of this study is to evaluate the safety and tolerability of BPI-15086.
Non-Small Cell Lung Cancer
DRUG: BPI-15086
Adverse events, Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, 18 months
Cmax, 4 weeks|Half life, 4 weeks|AUC, 4 weeks|Objective Response Rate, 12 weeks|Progression-Free Survival, 18 months
The main objective of this study is to evaluate the safety and tolerability of BPI-15086. In addition, the anti-cancer effect of BPI-15086 in EGFR T790M mutation-positive advanced NSCLC patients who have progressed on a previous EGFR tyrosine kinase inhibitor therapy will also be evaluated. Biomarkers related to the efficacy of BPI-15086 will be investigated.